Destroying some of the deadliest squamous cell cancers at their source
Corrixr is developing targeted genetic medicine designed to disable NRF2 in lung, head & neck, and esophageal squamous cell cancers
THE CHALLENGE
Lung, head & neck, and esophageal squamous cell carcinomas impact hundreds of thousands of patients each year and remain among the most treatment-resistant cancers in oncology.
For decades, treatment has relied on chemotherapy and radiation, therapies that destroy healthy tissue alongside cancerous cells and often impose severe toxicity.
Most patients endure aggressive cycles of treatment, diminished quality of life, and still face relapse.
THE CORRIXR APPROACH: Target the engine of survival
Lung, head & neck, and esophageal squamous tumors depend on NRF2 to survive.
The biology that initiates a tumor in these squamous cell cancers is not the same as the biology that sustains it. NRF2, a transcription factor chronically hyperactive in squamous cancers, drives survival.
Corrixr’s lead program, CXR101 is designed to disable NRF2, through localized genetic delivery directly to the tumor site.
WHY IT MATTERS
Designed with patients at the center.
Corrixr was founded on a simple belief: cancer treatment should destroy lung, head & neck, and esophageal squamous tumors without destroying patients’ quality of life.
Our targeted approach is designed to precisely attack squamous tumors while limiting systemic exposure and avoiding many of the challenges associated with traditional chemotherapy and radiation.
CXR101
Learn more about our pipeline.